Treatment of Tumor Cells with Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), Activates Monocytes Through Fc-FcyR Interaction and Immunogenic Cell Death
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.